# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pfreundschuh previously served as Chief Financial Officer at Voyager Therapeutics, Inc.
Truist Securities analyst Nicole Germino initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and annou...
HC Wainwright & Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price tar...
2024 Financial GuidanceManagement reiterates its full year 2024 guidance:Anticipated total DANYELZA® net product revenues of be...
Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $...
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical compa...